Whole Body Composition Analysis using Dual X-Ray Absorptiometry (DXA) or Bioelectrical Impedance Analysis (BIA)

This policy addresses whole-body composition analysis using dual-energy X‑ray absorptiometry (DXA) or bioelectrical impedance analysis (BIA) to quantify total and regional fat, lean and bone mass to inform diagnosis, prognosis, or treatment. It lists uses for patients with undernutrition or weight‑loss states (e.g., anorexia, cachexia, post‑bariatric or antiretroviral therapy with lipodystrophy), assessment of visceral fat for cardiometabolic risk, sarcopenia/aging, pediatric growth, and discordant BMI cases, but notes a major limitation that the policy is inactive and considers these tests experimental/investigational and not covered, citing accuracy, generalizability, and device/assumption‑related variability.

"Quantification and assessment of relative proportions of specific body compartments (e."

Sign up to see full coverage criteria, indications, and limitations.